Surveillance PET Scans After — Lymphoma Remission

Yes, in specific situations. If you develop new symptoms — a new lump, B symptoms such as fever, drenching night sweats, or unexplained weight loss, or anything that concerns your team — a PET scan is appropriate and will be ordered. Some patients on clinical trial protocols may have structured imaging built in. The guidance is against scans at fixed intervals when you have no symptoms; it is not a rule against scanning when there is clinical reason.

Follow-up schedules vary by lymphoma type and treatment history. A typical pattern involves more frequent visits in the first year or two, then less frequent visits as the risk of relapse decreases. Your team will give you your specific schedule. What matters at each visit is that you report new symptoms honestly, rather than assuming they are unrelated to lymphoma or not worth mentioning.

The clinical evidence is the primary driver. Studies have consistently found that surveillance PET does not detect relapse at a stage where earlier treatment changes the outcome compared with scanning after symptoms appear. The harm from false positives — anxiety, unnecessary procedures, and accumulated radiation — is real and documented. Cost is a secondary consideration, though for a test that does not improve outcomes, it is a relevant one.

A full blood count checks for changes in red cells, white cells, and platelets that can sometimes indicate disease activity. LDH — lactate dehydrogenase — is a marker that can rise when lymphoma cells are active, though it is non-specific and rises in many other conditions too. These tests are part of the routine picture your team builds at each visit, not a replacement for clinical assessment.

The recommendation against routine surveillance imaging applies to both, though the evidence base for Hodgkin lymphoma is particularly strong given the age of patients and the length of follow-up data available. DLBCL and other aggressive lymphomas also have guideline support against routine imaging after remission. Your specific subtype and any unusual features of your disease shape your individual follow-up plan — worth discussing directly with your haemato-oncologist.

You can, but discuss it with your haemato-oncologist first. A scan done without clinical context may produce a finding that is difficult to interpret — and a concerning result still leads back to the same team for assessment. Your oncologist can help you weigh whether a scan is likely to provide genuine reassurance or simply create new uncertainty. If something specific is worrying you, raising it directly is usually more useful than a scan.